Cure8 research brief
If you have moderate-to-severe UC and are treated with adalimumab (or other therapies), this study suggests the rectum may be slower or less likely to reach endoscopic and histologic healing than more proximal colon segments. That matters for how remission is assessed and for expectations about symptom resolution.
Clinicians managing UC, researchers studying mucosal healing or biologic therapy response, and patients with moderate-to-severe UC — especially those on adalimumab or other anti-TNF therapies.
The study evaluated patients who had baseline inflammation in at least one nonrectal colonic segment and received adalimumab; healing was measured both endoscopically (Mayo endoscopic subscore) and histologically (Robarts Histopathology Index) across colonic segments at weeks 8 and 52.
Across both short-term (week 8) and longer-term (week 52) assessments, the ascending and transverse colon showed larger mean score reductions and higher rates of endoscopic improvement/remission and histologic remission than the rectum.
The main takeaway is that even when overall disease activity improves on adalimumab, the rectum may lag behind proximal segments in both endoscopic and histologic healing, which could influence how clinicians assess mucosal healing and consider targeted management or monitoring.
Structured content depth is classified as an abstract from the journal; Cure8 did not review the full article beyond the extracted text. Findings are from the SERENE UC trial population with available full colonoscopies and segmental biopsies; applicability to all patients may be limited by trial inclusion criteria and sample size.
The abstract reports associations in segmental healing patterns but does not provide management recommendations.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A blood biomarker that helps predict primary non-response to anti‑TNF drugs could spare some patients ineffective therapy, reduce delays to alternative treatments, and inform shared decision‑making before starting...
A blood biomarker that predicts anti-TNF response could help people with IBD and their clinicians choose the right biologic sooner, avoiding ineffective treatment. This study reports that lower baseline serum oncostatin...
Patients on biologic therapy often have drug levels and antidrug antibodies measured to guide care. This study suggests prior biologic history, disease type (UC vs CD) and which biologic is currently used may affect...
